Effect of oral alendronate on net bone ingrowth into canine cementless total hips.

Alendronate has been shown to prevent osteolysis in a canine total hip arthroplasty (THA) model. However, the effect of alendronate on bone ingrowth and remodeling around canine cementless hip replacement components remains unclear. We hypothesized that oral alendronate would increase net bone ingrowth into the porous surface of THA components when intimate bone/implant contact exists.

The efficacy of BMP-2 to induce bone ingrowth in a total hip replacement model.

The purpose of this canine total hip arthroplasty (THA) study was fourfold: (1) to quantify the efficacy of rhBMP-2 in a carrier (alphaBSM) versus alphaBSM alone, and versus untreated controls to induce bone formation across a defect between a porous acetabular component and host bone; (2) to quantify whether rhBMP-2/alphaBSM improves bone growth into the porous surface beneath that defect; (3) to quantify the efficacy of rhBMP-2/alphaBSM in inducing bone ingrowth into the porous layer at points of intimate bone-implant contact; and (4) to determine whether rhBMP-2/alphaBSM placed in the lateral uncovered aspect of the porous acetabular component promotes de novo bone formation. Fifteen dogs were sacrificed 12 weeks after uncemented THA. Five dogs received rhBMP-2/alphaBSM, five dogs received alphaBSM, and five dogs were controls.